Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Bromfenac monosodium salt sesquihydrate

Bromfenac monosodium salt sesquihydrate

pharmaceutical raw materials
Bromfenac monosodium salt sesquihydrate structure

Bromfenac monosodium salt sesquihydrate 

structure
  • CAS No:

    120638-55-3

  • Formula:

    C15H11BrNNaO3

  • Chemical Name:

    Bromfenac monosodium salt sesquihydrate

  • Synonyms:

    Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate;Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, hydrate (2:3);Bromfenac ophthalmic;Bromfenac ophthalmic solution;Duract;Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate;Unii-8ecv571Y37;Bromfenac monosodium salt sesquihydrate

  • Categories:

    Pharmaceutical Intermediates  >  Ophthalmic Agents

Description

Duract was launched in the US as a potent, orally-active, long lasting peripheral analgesic with antiinflammatory properties. It is structurally similar to ketoprofen and diclofenac and can be prepared in three steps from 2-amino-4’-bromophenone using Gassman’s oxindole synthesis. Duract’s biological effects are a result of its ability to reduce prostaglandin production through inhibition of cyclooxygenase. As a 4-bromo derivative of Amfenac, this modification increased the duration of analgesic activity and antiinflammatory potency. It was also free of any CNS, cardiovascular or autonomic effects. In comparison, 5 mg of Duract was equipotent to 650 mg of ASA and 25 mg was slightly more potent than 400 mg of Ibuprofen.


Yellow Solid


ChEBI: The sesquihydrate of the sodium salt of bromfenac. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction.

Bromfenac monosodium salt sesquihydrate Basic Attributes

356.15

695-342-6

Light yellow to yellow

Characteristics

268-270°C (dec.)

Refrigerator

Bromfenac monosodium salt sesquihydrate Use and Manufacturing

Bromfenac (Xibrom, ISTA Pharmaceuticals, Irvine, USA; Bronuck, Senju Pharmaceutical, Osaka, Japan) is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients after undergoing cataract extraction. For this task, one drop of Xibrom may be applied to the affected eye twice daily beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period. The clinical safety and efficacy of bromfenac have been extensively studied in diverse comparative investigations, including the treatment of external or anterior ocular inflammatory diseases, allergic conjunctivitis, scleritis, and postoperative inflammation.The results of two phase III multicenter, randomized double-masked placebo-controlled clinical trials showed that bromfenac ophthalmic solution 0.09% was effective in the rapid resolution of ocular pain after cataract surgery, and there was a statistically significant difference between the bromfenac and placebo groups demonstrated in these phase III clinical trials.


Bromfenac is a non-steroidal anti-inflammatory agent.

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • MICRO LABS LIMITED

    India India
    Active
  • Guangzhou Huasheng Pharmaceutical Co., Ltd.

    China China
    Active
  • Wuhan Leadpharm Pharmaceutical Technology Co., Ltd.

    China China
    Active

Recommended Suppliers of Bromfenac monosodium salt sesquihydrate

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.